RT Journal Article
SR Electronic
T1 The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.23.22280188
DO 10.1101/2022.09.23.22280188
A1 Prins, H.A.B.
A1 Crespo, R.
A1 Lungu, C.
A1 Rao, S.
A1 Li, L.
A1 Overmars, R.J.
A1 Papageorgiou, G.
A1 Mueller, Y.M.
A1 Hossain, T.
A1 Kan, T.W.
A1 Rijnders, B.J.A.
A1 Bax, H.I.
A1 van Gorp, E.C.M.
A1 Nouwen, J.L.
A1 de Vries-Sluijs, T.E.M.S.
A1 Schurink, C.A.M.
A1 de Mendonça Melo, M.
A1 van Nood, E.
A1 Colbers, A.
A1 Burger, D.
A1 Palstra, R-J.
A1 van Kampen, J.J.A.
A1 van de Vijver, D.A.M.C.
A1 Mesplède, T.
A1 Katsikis, P.D.
A1 Gruters, R.A.
A1 Koch, B.C.P.
A1 Verbon, A.
A1 Mahmoudi, T.
A1 Rokx, C.
YR 2022
UL http://medrxiv.org/content/early/2022/09/23/2022.09.23.22280188.abstract
AB A major barrier towards HIV-1 cure is the presence of a replication-competent latent reservoir that, upon treatment cessation, can spark viral rebound leading to disease progression. Pharmacological reactivation of the latent HIV-1 reservoir with Latency reversing agents (LRAs) is a first step toward triggering reservoir decay. Inhibitors of the BAF-complex, a key repressor of HIV-1 transcription were identified to act as LRAs, and enhanced the effect of other LRAs such as histone deacetylase inhibitors ex-vivo. We repurposed the licensed drug pyrimethamine as a BAF-inhibitor to investigate its in vivo impact on the HIV-1 reservoir of people living with HIV-1 (PLWH). Twenty eight PLWH on suppressive antiviral therapy were randomized in a 1:1:1:1 ratio to receive pyrimethamine; high dose valproic acid; both valproic acid and pyrimethamine; or no intervention for 14 days. The primary endpoint was change in HIV-1 reactivation measured as cell associated (CA)HIV-1 RNA at treatment initiation and at the end of treatment. We observed a rapid, modest and significant increase in CAHIV-1 RNA in CD4+T-cells in response to pyrimethamine exposure, which persisted throughout the 14 day treatment, concomitant with induction of BAF target genes as biomarkers of pyrimethamine activity as well as detected plasma pyrimethamine levels. Valproic acid treatment alone did not lead to increase in CAHIV-1 RNA, nor did valproic acid augment the latency reversal effect of pyrimethamine. Despite demonstrated latency reversal, pyrimethamine treatment did not result in a reduction in the size of the inducible reservoir as determined by a tat/rev limiting dilution assay. Serious adverse events were not observed, although physician-directed treatment adjustments occurred, particularly when combining valproic acid with pyrimethamine. These data underline the need for pharmacovigilance in combinatorial clinical strategies and demonstrate that the BAF inhibitor pyrimethamine reverses HIV-1 latency in vivo in PLWH, substantiating its potential in advancement in clinical studies to target the proviral reservoir. Clinicaltrials.gov:NCT03525730One sentence summary This clinical trial shows that the BAF inhibitor pyrimethamine reverses HIV-1 latency in vivo which supports repurposing this drug for cure studies.Competing Interest StatementJvK reports research grants from NIH and ZonMW, an advisory board membership for Gilead Sciences, and consultancy for HaDEA. DB report research grants from ViiV Healthcare, Gilead, Merck and acted as an advisor to ViiV Healthcare, Gilead, Merck and Pfizer. RAG reports research grants from NIH, Health~Holland, EU and Aidsfonds. PDK reports funding from Aidsfonds. CR reports research grants from ViiV Healthcare, Gilead sciences, Janssen-Cilag, Health~Holland, Erasmus MC, Aidsfonds, ZonMW, Dutch Federation Medical Specialist, advisory board membership and travel reimbursement from ViiV Healthcare and Gilead sciences. All others declare no conflict of interest.Clinical TrialNCT03525730Funding StatementCR received funding from ErasmusMC MRace (project nr.: 108172), Aidsfonds (grant nr.: P-53601). SR received funding from Aidsfonds (grant nr: P-53102). RG received funding from Horizon Europe (grant nr. 681032), TM received funding from Health Holland (grant nrs.: LSHM19100-SGF and EMCLSH19023) and ZonMW (grant nr.: 40-44600-98-333).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Research Ethics Committee (MEC-2017-476) of Erasmus Medical Center gave ethical approval for this work in accordance with the principles of the Helsinki DeclarationI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, code, and materials used in the analysis are available to any researcher for purposes of reproducing or extending the analysis upon request and approval by both corresponding authors.